SIMCERE PHARMA (02096) saw its stock price surge 5.32% in pre-market trading on Friday, following the release of impressive half-year results and the announcement of a share repurchase program. The pharmaceutical company's strong performance and shareholder-friendly move have sparked investor enthusiasm.

The company reported robust financial results for the first half of 2025, with revenue reaching RMB 3.585 billion, representing a significant year-on-year increase of 15.14%. Net profit climbed to RMB 604 million, marking a substantial 32.2% rise compared to the same period last year. Basic earnings per share stood at RMB 0.25. Notably, the company's adjusted profit attributable to equity shareholders rose by 21.1% to RMB 651 million, up from RMB 538 million in the previous year.

Adding to the positive sentiment, SIMCERE PHARMA's board has resolved to implement a share repurchase program of up to RMB 500 million. This move is likely viewed favorably by investors, as it demonstrates the company's confidence in its future prospects and commitment to enhancing shareholder value. The combination of strong financial performance and the share buyback announcement appears to be driving the stock's pre-market rally.